Cellzome and Exelixis have independently designed the first highly selective inhibitors of the gamma-isoform of PI3K. Exelixis hopes to out-license its inhibitors, whereas the recent acquisition of Cellzome by GlaxoSmithKline gives the pharma a new class of compounds for inflammatory and autoimmune diseases.